The full effect of the introduction of quadrivalent flu vaccines is unlikely to become clear for several years, but this week saw the release of data that convinced the FDA to approve GlaxoSmithKline's vaccine. And while the benefit of the extra strain is unclear, the data makes a case for immunizing with any flu vaccine.
China is a big, climatologically-diverse country, with the weather changing significantly between the temperate zones in the north and the subtropical regions further south. This affects when flu seasons occur, and consequently when health authorities should run vaccination campaigns.
U.K. health authorities have run similar surveys over the past four years, but this is the first time it will capture data from schools.
Navy sailors may have received ineffective vaccines because of a failure to keep the products at the right temperature, Navy Times reports.
The discovery of a correlation between the flu vaccine and decreased risk of heart attack was met with skepticism earlier this year, particularly in light of GlaxoSmithKline's financial support of the study. But now, several months later, a new, more definitive analysis has identified the same trend.
Researchers at St. Jude's Children's Research Hospital have developed a new approach for creating an influenza vaccine that could guard against multiple flu strains, including pandemic ones.
While the government shutdown has cast doubt on the Centers for Disease Control and Prevention's (CDC) ability to manage the upcoming flu season, officials can take some solace from last year's efforts. Flu vaccine uptake levels in adults, kids and health workers all trended upward last year.
Congress' failure to find a budget compromise and subsequent government shutdown has left CDC without the staff to carry out many of its functions, including the seasonal influenza program.
The vaccine sector appears to be in good health. After coming through a period in which low profit margins and liability concerns deterred investment, EvaluatePharma now tips the sector to grow from $25 billion to $39 billion between 2012 and 2018. Yet, in some areas, old complaints can still be heard.
Cambridge, MA-based Visterra has unveiled positive preclinical data showing that its lead antibody candidate, VIS410, neutralized strains of H5N1 and H7N9 influenza in mice.